In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 ( HER2 ) , progression-free survival was significantly improved after first-line therapy with pertuzumab , trastuzumab , and docetaxel , as compared with placebo , trastuzumab , and docetaxel .